Gilead’s $84,000 Treatment Questioned by U.S. Lawmakers
This article is for subscribers only.
Gilead Sciences Inc. is being asked by U.S. House Democrats to explain how the company set its $84,000 price for hepatitis C treatment Sovaldi.
The lawmakers also asked Gilead Chief Executive Officer John Martin to explain what is being done to make sure the medicine gets into the hands of low-income patients, especially in government-run health programs.